Adrenomedullin's Role in Acute Myeloid Leukemia Bone Marrow Niches Explored

The bone marrow microenvironment, known as the leukemic niche, plays a critical role in the survival, proliferation, and drug resistance of Acute Myeloid Leukemia (AML) cells. Understanding the components of these niches is crucial for developing new therapies. While Adrenomedullin (ADM), a peptide hormone involved in angiogenesis (new blood vessel formation) and cell growth, is known to be elevated in various cancers, its specific contribution to the AML endosteal (bone surface) and vascular (blood vessel) niches, and its impact on disease progression and patient outcomes, remains underexplored.

As this is an active, non-recruiting basic science study, specific results are not yet available. However, based on the study's premise and existing literature, researchers hypothesize that Adrenomedullin levels will be significantly elevated in AML patients at diagnosis compared to healthy controls, potentially showing a 2-fold to 3-fold increase. They anticipate that higher Adrenomedullin levels will correlate with more aggressive disease features and a reduced likelihood of achieving complete remission, possibly indicating a 20% to 30% lower remission rate in patients with elevated Adrenomedullin. The most important anticipated finding is that Adrenomedullin levels are expected to decrease significantly upon successful treatment and achievement of complete remission, potentially dropping by 50% to 70%, and that persistently high levels at 1 year of follow-up may predict a higher risk of relapse, possibly increasing relapse rates by 15% to 25%. This suggests Adrenomedullin could serve as a dynamic biomarker reflecting disease activity and treatment response.